Galectin Therapeutics (GALT) Short Interest Ratio & Short Volume $1.49 +0.02 (+1.36%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.48 0.00 (-0.34%) As of 02/21/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Galectin Therapeutics Short Interest DataGalectin Therapeutics (GALT) has a short interest of 7.98 million shares, representing 18.48% of the float (the number of shares available for trading by the public). This marks a -2.21% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.2, indicating that it would take 11.2 days of the average trading volume of 327,180 shares to cover all short positions.Current Short Interest7,980,000 sharesPrevious Short Interest8,160,000 sharesChange Vs. Previous Month-2.21%Dollar Volume Sold Short$9.98 millionShort Interest Ratio11.2 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares62,760,000 sharesFloat Size43,180,000 sharesShort Percent of Float18.48%Today's Trading Volume267,208 sharesAverage Trading Volume327,180 sharesToday's Volume Vs. Average82% Short Selling Galectin Therapeutics? Sign up to receive the latest short interest report for Galectin Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGALT Short Interest Over TimeGALT Days to Cover Over TimeGALT Percentage of Float Shorted Over Time Galectin Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/20257,980,000 shares $9.98 million -2.2%18.5%11.2 $1.25 1/15/20258,160,000 shares $10.44 million +1.5%18.9%11.8 $1.28 12/31/20248,040,000 shares $10.37 million -2.8%18.5%12.1 $1.29 12/15/20248,270,000 shares $17.45 million +41.1%19.0%16.7 $2.11 11/30/20245,860,000 shares $16.94 million +2.8%13.5%26.7 $2.89 11/15/20245,700,000 shares $15.79 million +3.3%13.1%40.3 $2.77 10/31/20245,520,000 shares $13.63 million +1.1%12.8%42.9 $2.47 10/15/20245,460,000 shares $14.20 million +1.5%12.6%45 $2.60 9/30/20245,380,000 shares $14.80 million +2.3%12.4%43.7 $2.75 9/15/20245,260,000 shares $15.10 million +4.0%12.2%30.9 $2.87 Get the Latest News and Ratings for GALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20245,060,000 shares $13.64 million +1.0%11.7%29.8 $2.70 8/15/20245,010,000 shares $10.97 million +6.4%11.6%30.3 $2.19 7/31/20244,710,000 shares $11.78 million +3.1%10.9%26.7 $2.50 7/15/20244,570,000 shares $10.88 million +14.0%10.7%24 $2.38 6/30/20244,010,000 shares $9.06 million +1.5%9.4%18 $2.26 6/15/20243,950,000 shares $10.35 million +3.4%9.3%20.3 $2.62 5/31/20243,820,000 shares $10.39 million +2.4%9.0%20.2 $2.72 5/15/20243,730,000 shares $11.41 million +19.6%8.8%20.4 $3.06 4/30/20243,120,000 shares $10.95 million +13.9%7.4%18.8 $3.51 4/15/20242,740,000 shares $10.71 million +21.8%6.5%18.7 $3.91 3/31/20242,250,000 shares $5.38 million +5.1%5.3%21.3 $2.39 3/15/20242,140,000 shares $4.41 million +1.9%5.1%29.4 $2.06 2/29/20242,100,000 shares $4.11 million +1.0%5.0%30.6 $1.96 2/15/20242,080,000 shares $3.64 million No Change4.9%33.3 $1.75 1/31/20242,080,000 shares $3.52 million -0.5%4.9%32.8 $1.69 1/15/20242,090,000 shares $3.85 million -1.0%5.0%34 $1.84 12/31/20232,110,000 shares $3.50 million -0.9%5.0%33.8 $1.66 12/15/20232,130,000 shares $3.41 million +1.0%5.0%33.7 $1.60 11/30/20232,110,000 shares $4.11 million +8.2%5.0%36.9 $1.95 11/15/20231,950,000 shares $3.65 million No Change4.6%37.3 $1.87 10/31/20231,950,000 shares $3.98 million +3.7%4.7%39.3 $2.04 10/15/20231,880,000 shares $3.78 million -5.5%4.5%35.9 $2.01 9/30/20231,990,000 shares $3.82 million -1.5%4.8%36.1 $1.92 9/15/20232,020,000 shares $3.56 million No Change4.8%40.3 $1.76 8/31/20232,020,000 shares $3.54 million +2.5%4.8%35.7 $1.75 8/15/20231,970,000 shares $3.15 million -3.4%4.7%32.2 $1.60 7/31/20232,040,000 shares $3.06 million -1.5%4.8%33.6 $1.50 7/15/20232,070,000 shares $3.37 million -3.3%4.9%35 $1.63 6/30/20232,140,000 shares $3.08 million +2.9%5.1%37.4 $1.44 6/15/20232,080,000 shares $3.04 million -0.5%4.9%35.4 $1.46We recommended Palantir in 2021, now we’re recommending this... (Ad)I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nice stream of income along the way.Our research indicates ONE AI stock is poised to benefit the most. 5/31/20232,090,000 shares $3.28 million -1.4%5.0%40.3 $1.57 5/15/20232,120,000 shares $3.48 million +0.5%5.0%29.1 $1.64 4/30/20232,110,000 shares $3.71 million No Change5.0%22.8 $1.76 4/15/20232,110,000 shares $4.24 million No Change5.0%21.6 $2.01 3/31/20232,110,000 shares $4.43 million -0.5%5.0%21.4 $2.10 3/15/20232,120,000 shares $4.03 million +5.0%5.0%18.5 $1.90 2/28/20232,020,000 shares $4.18 million No Change4.8%17.2 $2.07 2/15/20232,020,000 shares $2.91 million +3.1%4.8%20.5 $1.44 1/31/20231,960,000 shares $2.27 million -1.5%4.6%19.7 $1.16 1/15/20231,990,000 shares $2.27 million -0.5%4.7%24.8 $1.14 12/30/20222,000,000 shares $2.26 million -1.5%4.7%22.7 $1.13 12/15/20222,030,000 shares $2.35 million +0.5%4.8%26.6 $1.16 11/30/20222,020,000 shares $2.57 million -0.5%4.8%32.8 $1.27 11/15/20222,030,000 shares $2.52 million -1.5%4.8%33.7 $1.24 10/31/20222,060,000 shares $2.84 million -3.7%4.9%33.9 $1.38 10/15/20222,140,000 shares $3.47 million +3.4%5.0%29.6 $1.62 9/30/20222,070,000 shares $3.37 million No Change4.9%29.8 $1.63 9/15/20222,070,000 shares $3.71 million -1.4%4.9%26.7 $1.79 8/31/20222,100,000 shares $3.99 million -1.4%4.9%24.9 $1.90 8/15/20222,130,000 shares $4.64 million -0.5%5.0%22.6 $2.18 7/31/20222,140,000 shares $4.84 million +0.9%5.0%21.4 $2.26 7/15/20222,120,000 shares $3.50 million -2.8%5.0%22.5 $1.65 6/30/20222,180,000 shares $2.86 million -1.8%5.1%19.7 $1.31 6/15/20222,220,000 shares $2.82 million +3.7%6.5%18.9 $1.27 5/31/20222,140,000 shares $2.76 million -1.4%5.0%18.8 $1.29 5/15/20222,170,000 shares $2.95 million -9.6%5.1%19.7 $1.36 4/30/20222,400,000 shares $3.72 million +7.6%5.6%23 $1.55 4/15/20222,230,000 shares $3.88 million +9.9%5.2%19.8 $1.74 3/31/20222,030,000 shares $3.27 million +2.5%4.8%20.1 $1.61 3/15/20221,980,000 shares $3.45 million +7.0%4.6%17.6 $1.74 2/28/20221,850,000 shares $3.46 million -5.6%4.3%14.7 $1.87 2/15/20221,960,000 shares $4.06 million -1.0%4.6%14.5 $2.07 1/31/20221,980,000 shares $3.82 million No Change4.6%12.7 $1.93 1/15/20221,980,000 shares $4.00 million +4.2%4.6%12.5 $2.02 12/31/20211,900,000 shares $3.93 million -11.6%4.4%11.8 $2.07 12/15/20212,150,000 shares $4.84 million -4.4%5.0%12.4 $2.25 11/30/20212,250,000 shares $5.92 million -1.8%5.3%11.2 $2.63 11/15/20212,290,000 shares $6.55 million +5.5%5.4%9.3 $2.86 10/29/20212,170,000 shares $6.88 million -11.4%5.1%8 $3.17 10/15/20212,450,000 shares $8.26 million +3.8%5.7%6.9 $3.37 9/30/20212,360,000 shares $9.16 million -13.9%5.5%4.7 $3.88 9/15/20212,740,000 shares $10.22 million -7.4%6.4%1.3 $3.73 8/31/20212,960,000 shares $11.63 million -18.2%7.0%1.3 $3.93 8/13/20213,620,000 shares $12.24 million +17.5%8.5%1.6 $3.38 7/30/20213,080,000 shares $8.47 million -9.9%7.4%1.4 $2.75 7/15/20213,420,000 shares $8.86 million +25.7%8.2%1.3 $2.59 6/30/20212,720,000 shares $8.70 million -40.6%6.5%0.7 $3.20 6/15/20214,580,000 shares $16.03 million +11.2%11.0%1.8 $3.50 5/28/20214,120,000 shares $16.36 million -22.9%10.0%1.6 $3.97 5/14/20215,340,000 shares $22.48 million -2.2%12.9%2.1 $4.21We recommended Palantir in 2021, now we’re recommending this... (Ad)I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nice stream of income along the way.Our research indicates ONE AI stock is poised to benefit the most. 4/30/20215,460,000 shares $23.15 million +12.4%13.4%2.2 $4.24 4/15/20214,860,000 shares $11.47 million +1.9%12.0%2.3 $2.36 3/31/20214,770,000 shares $9.68 million +2.4%11.8%7.7 $2.03 3/15/20214,660,000 shares $10.76 million +0.7%11.5%14.8 $2.31 2/26/20214,630,000 shares $10.60 million -0.9%11.4%14.4 $2.29 2/12/20214,670,000 shares $11.25 million +3.6%11.5%15.1 $2.41 1/29/20214,510,000 shares $8.93 million -0.4%11.1%15.9 $1.98 1/15/20214,530,000 shares $10.10 million -5.0%11.2%18.8 $2.23 12/31/20204,770,000 shares $10.97 million -3.3%11.8%21.3 $2.30 12/15/20204,930,000 shares $12.47 million -2.2%12.2%15.3 $2.53 11/30/20205,040,000 shares $13.36 million -2.0%12.4%16.2 $2.65 11/15/20205,140,000 shares $14.14 million -1.7%12.7%17.2 $2.75 10/30/20205,230,000 shares $13.65 million -2.2%12.9%17 $2.61 10/15/20205,350,000 shares $14.77 million +0.8%13.2%17.5 $2.76 9/30/20205,310,000 shares $14.18 million +4.1%13.0%18.8 $2.67 9/15/20205,100,000 shares $14.94 million -3.8%12.5%29.7 $2.93 8/31/20205,300,000 shares $14.05 million -1.3%13.0%30.8 $2.65 8/14/20205,370,000 shares $16.49 million -2.2%13.1%30.2 $3.07 7/31/20205,490,000 shares $14.33 million -1.4%13.4%29.8 $2.61 7/15/20205,570,000 shares $15.32 million +0.4%13.6%22.7 $2.75 6/30/20205,550,000 shares $16.87 million +1.7%13.6%21.2 $3.04 6/15/20205,460,000 shares $15.07 million -0.4%13.3%21.4 $2.76 5/29/20205,480,000 shares $16.17 million -0.5%13.4%19.5 $2.95 5/15/20205,510,000 shares $15.65 million -1.6%13.5%18.5 $2.84 4/30/20205,600,000 shares $13.92 million +10.0%13.7%19.7 $2.49 4/15/20205,090,000 shares $8.91 million No Change12.4%22.3 $1.75 3/31/20205,090,000 shares $9.57 million -5.1%12.5%22.8 $1.88 3/13/20205,364,800 shares $9.87 million +0.7%13.2%23.9 $1.84 2/28/20205,330,000 shares $9.17 million +4.1%13.1%23.5 $1.72 GALT Short Interest - Frequently Asked Questions What is Galectin Therapeutics' current short interest? Short interest is the volume of Galectin Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 7,980,000 shares of GALT short. 18.48% of Galectin Therapeutics' shares are currently sold short. Learn More on Galectin Therapeutics' current short interest. What is a good short interest ratio for Galectin Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GALT shares currently have a short interest ratio of 11.0. Learn More on Galectin Therapeutics's short interest ratio. Which institutional investors are shorting Galectin Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Galectin Therapeutics: Wolverine Trading LLC, LMR Partners LLP, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Boothbay Fund Management LLC, HAP Trading LLC, Concourse Financial Group Securities Inc., Affinity Asset Advisors LLC, ADAR1 Capital Management LLC, and FNY Investment Advisers LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Galectin Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 18.48% of Galectin Therapeutics' floating shares are currently sold short. Is Galectin Therapeutics' short interest increasing or decreasing? Galectin Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totaling 7,980,000 shares, a decrease of 2.2% from the previous total of 8,160,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Galectin Therapeutics' float size? Galectin Therapeutics currently has issued a total of 62,760,000 shares. Some of Galectin Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Galectin Therapeutics currently has a public float of 43,180,000 shares. How does Galectin Therapeutics' short interest compare to its competitors? 18.48% of Galectin Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Galectin Therapeutics: Aurora Cannabis Inc. (9.31%), Terns Pharmaceuticals, Inc. (10.35%), Foghorn Therapeutics Inc. (3.53%), Taysha Gene Therapies, Inc. (11.75%), Cryoport, Inc. (4.22%), Annexon, Inc. (9.47%), Corvus Pharmaceuticals, Inc. (9.51%), Trevi Therapeutics, Inc. (5.97%), COMPASS Pathways plc (6.53%), Aquestive Therapeutics, Inc. (12.16%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Galectin Therapeutics stock? Short selling GALT is an investing strategy that aims to generate trading profit from Galectin Therapeutics as its price is falling. GALT shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Galectin Therapeutics? A short squeeze for Galectin Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GALT, which in turn drives the price of the stock up even further. How often is Galectin Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GALT, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies ACB Short Interest Data TERN Short Interest Data FHTX Short Interest Data TSHA Short Interest Data CYRX Short Interest Data ANNX Short Interest Data CRVS Short Interest Data TRVI Short Interest Data CMPS Short Interest Data AQST Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GALT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts